Annual EBIT
-$209.15 M
-$62.95 M-43.06%
December 31, 2023
Summary
- As of February 7, 2025, SNDX annual earnings before interest & taxes is -$209.15 million, with the most recent change of -$62.95 million (-43.06%) on December 31, 2023.
- During the last 3 years, SNDX annual EBIT has fallen by -$138.35 million (-195.41%).
- SNDX annual EBIT is now -879.69% below its all-time high of $26.82 million, reached on December 31, 2021.
Performance
SNDX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$84.10 M
-$16.09 M-23.65%
September 30, 2024
Summary
- As of February 7, 2025, SNDX quarterly earnings before interest & taxes is -$84.10 million, with the most recent change of -$16.09 million (-23.65%) on September 30, 2024.
- Over the past year, SNDX quarterly EBIT has dropped by -$33.03 million (-64.66%).
- SNDX quarterly EBIT is now -187.43% below its all-time high of $96.19 million, reached on December 31, 2021.
Performance
SNDX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$296.88 M
-$33.03 M-12.52%
September 30, 2024
Summary
- As of February 7, 2025, SNDX TTM earnings before interest & taxes is -$296.88 million, with the most recent change of -$33.03 million (-12.52%) on September 30, 2024.
- Over the past year, SNDX TTM EBIT has dropped by -$120.98 million (-68.78%).
- SNDX TTM EBIT is now -1206.71% below its all-time high of $26.82 million, reached on December 31, 2021.
Performance
SNDX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
SNDX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -43.1% | -64.7% | -68.8% |
| 3 y3 years | -195.4% | -130.3% | -1805.5% |
| 5 y5 years | -182.8% | -130.3% | -1805.5% |
SNDX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -879.7% | at low | -187.4% | at low | -1206.7% | at low |
| 5 y | 5-year | -879.7% | at low | -187.4% | at low | -1206.7% | at low |
| alltime | all time | -879.7% | at low | -187.4% | at low | -1206.7% | at low |
Syndax Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$84.10 M(+23.6%) | -$296.88 M(+12.5%) |
| Jun 2024 | - | -$68.02 M(-6.0%) | -$263.85 M(+9.7%) |
| Mar 2024 | - | -$72.34 M(-0.1%) | -$240.41 M(+14.9%) |
| Dec 2023 | -$209.15 M(+43.1%) | -$72.41 M(+41.8%) | -$209.15 M(+18.9%) |
| Sep 2023 | - | -$51.08 M(+14.6%) | -$175.89 M(+11.0%) |
| Jun 2023 | - | -$44.58 M(+8.5%) | -$158.47 M(+5.1%) |
| Mar 2023 | - | -$41.09 M(+4.9%) | -$150.77 M(+3.1%) |
| Dec 2022 | -$146.20 M(-645.0%) | -$39.15 M(+16.3%) | -$146.20 M(+1246.4%) |
| Sep 2022 | - | -$33.66 M(-8.7%) | -$10.86 M(-487.0%) |
| Jun 2022 | - | -$36.88 M(+1.0%) | $2.81 M(-83.9%) |
| Mar 2022 | - | -$36.52 M(-138.0%) | $17.41 M(-35.1%) |
| Dec 2021 | $26.82 M(-137.9%) | $96.19 M(-581.2%) | $26.82 M(-130.1%) |
| Sep 2021 | - | -$19.99 M(-10.3%) | -$89.15 M(+0.2%) |
| Jun 2021 | - | -$22.28 M(-17.8%) | -$88.97 M(+7.0%) |
| Mar 2021 | - | -$27.10 M(+37.0%) | -$83.11 M(+17.4%) |
| Dec 2020 | -$70.80 M(+26.3%) | -$19.79 M(-0.1%) | -$70.80 M(+8.9%) |
| Sep 2020 | - | -$19.80 M(+20.6%) | -$65.01 M(+12.0%) |
| Jun 2020 | - | -$16.42 M(+11.1%) | -$58.04 M(+2.7%) |
| Mar 2020 | - | -$14.79 M(+5.6%) | -$56.53 M(+0.9%) |
| Dec 2019 | -$56.05 M(-24.2%) | -$14.00 M(+9.1%) | -$56.05 M(-5.7%) |
| Sep 2019 | - | -$12.83 M(-14.0%) | -$59.47 M(-7.8%) |
| Jun 2019 | - | -$14.92 M(+4.3%) | -$64.48 M(-5.9%) |
| Mar 2019 | - | -$14.30 M(-17.9%) | -$68.51 M(-7.4%) |
| Dec 2018 | -$73.96 M | -$17.42 M(-2.4%) | -$73.96 M(-2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$17.84 M(-5.9%) | -$76.03 M(+3.3%) |
| Jun 2018 | - | -$18.95 M(-4.1%) | -$73.64 M(+7.5%) |
| Mar 2018 | - | -$19.75 M(+1.3%) | -$68.53 M(+10.6%) |
| Dec 2017 | -$61.95 M(+41.6%) | -$19.49 M(+26.2%) | -$61.95 M(+15.6%) |
| Sep 2017 | - | -$15.45 M(+11.6%) | -$53.61 M(+0.4%) |
| Jun 2017 | - | -$13.84 M(+5.0%) | -$53.40 M(+10.8%) |
| Mar 2017 | - | -$13.18 M(+18.3%) | -$48.19 M(+10.1%) |
| Dec 2016 | -$43.77 M(+113.4%) | -$11.14 M(-26.9%) | -$43.77 M(+17.3%) |
| Sep 2016 | - | -$15.24 M(+76.5%) | -$37.30 M(+33.6%) |
| Jun 2016 | - | -$8.63 M(-1.4%) | -$27.92 M(+12.5%) |
| Mar 2016 | - | -$8.75 M(+87.1%) | -$24.83 M(+21.1%) |
| Dec 2015 | -$20.51 M(-3.8%) | -$4.68 M(-20.1%) | -$20.51 M(+7.3%) |
| Sep 2015 | - | -$5.86 M(+5.7%) | -$19.12 M(-8.9%) |
| Jun 2015 | - | -$5.54 M(+25.0%) | -$21.00 M(-3.6%) |
| Mar 2015 | - | -$4.43 M(+34.8%) | -$21.78 M(+2.1%) |
| Dec 2014 | -$21.33 M(+148.9%) | -$3.29 M(-57.5%) | -$21.33 M(+2.0%) |
| Sep 2014 | - | -$7.74 M(+22.3%) | -$20.92 M(+35.2%) |
| Jun 2014 | - | -$6.32 M(+58.8%) | -$15.47 M(+37.6%) |
| Mar 2014 | - | -$3.98 M(+38.3%) | -$11.24 M(+31.2%) |
| Dec 2013 | -$8.57 M(-1.9%) | -$2.88 M(+26.1%) | -$8.57 M(+50.6%) |
| Sep 2013 | - | -$2.28 M(+8.9%) | -$5.69 M(+67.0%) |
| Jun 2013 | - | -$2.10 M(+60.0%) | -$3.41 M(+160.0%) |
| Mar 2013 | - | -$1.31 M | -$1.31 M |
| Dec 2012 | -$8.73 M | - | - |
FAQ
- What is Syndax Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals annual EBIT year-on-year change?
- What is Syndax Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals quarterly EBIT year-on-year change?
- What is Syndax Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals TTM EBIT year-on-year change?
What is Syndax Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of SNDX is -$209.15 M
What is the all time high annual EBIT for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high annual earnings before interest & taxes is $26.82 M
What is Syndax Pharmaceuticals annual EBIT year-on-year change?
Over the past year, SNDX annual earnings before interest & taxes has changed by -$62.95 M (-43.06%)
What is Syndax Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of SNDX is -$84.10 M
What is the all time high quarterly EBIT for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high quarterly earnings before interest & taxes is $96.19 M
What is Syndax Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, SNDX quarterly earnings before interest & taxes has changed by -$33.03 M (-64.66%)
What is Syndax Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of SNDX is -$296.88 M
What is the all time high TTM EBIT for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high TTM earnings before interest & taxes is $26.82 M
What is Syndax Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, SNDX TTM earnings before interest & taxes has changed by -$120.98 M (-68.78%)